Alzheimer's Disease and Dementia
Featured Topics
Lead story
Other featured articles
-
Key Barriers for Clinical Trials for Alzheimer’s Disease
Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.
Posted in -
Research Spotlight: Alzheimer’s Disease
Schaeffer Center researchers are analyzing trends associated with a greying population, including AD prevalence and cost, and what these trends mean for society.
Posted in -
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for future advances in Alzheimer’s disease (AD) made in 2001 and projects future breakthroughs over the next 20 years.
Posted in -
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Posted in
About this section
Even small delays in the onset of Alzheimer's disease and dementia could have significant impacts for the patient, their family and caregivers, and the healthcare system more broadly. The Schaeffer Center's microsimulation models demonstrate there may be preventive measures we can take now to shape the nation's future health.
OUR EXPERTS ON ALZHEIMER'S DISEASE AND DEMENTIA PREVENTION
Our Work In Alzheimer's Disease and Dementia
-
Information Session for Schaeffer Center Pilot Funding
Join us on Tuesday, January 12 to learn more about upcoming pilot funding opportunities through Schaeffer Center for Roybal Center for Behavioral Interventions in Aging, CeASES-ADRD and USC Alzheimer’s Disease Resource Center for Minority Aging Health Economics Research.
-
Applying for the 2021-2022 CeASES-ADRD Pilot Award
The Schaeffer Center, through the USC Center for Advancing Sociodemographic and Economic Study of Alzheimer’s Disease and Related Dementias (CeASES-ADRD), is currently accepting applications to fund one-year research pilot projects.
-
Cognitive Assessment At Medicare’s Annual Wellness Visit In Fee-For-Service And Medicare Advantage Plans
The study provides new insights – the self-reports of survey respondents – into cognitive assessments at annual wellness visits, an area that has been somewhat hidden from view.
Categorized in -
Most Medicare Beneficiaries Say They Don’t Receive Structured Cognitive Assessments at Wellness Visits
The results reinforce the need to evaluate policies and practices around detecting impairment, according to the researchers.
-
Research, Advocacy, and the Fight Against Alzheimer’s
Join Dana Goldman in conversation with Paul Aisen and Lauren Miller Rogen for a discussion about research, advocacy, and bringing awareness to Alzheimer’s.
-
After Decades of Disappointment, a Turning Point Is Visible in Alzheimer’s Treatment
The USC-Brookings Schaeffer Initiative for Health Policy hosted a webinar featuring national thought leaders to examine hopeful signs in clinical development and policy that will ensure access to treatments and diagnostics.
Categorized in